Methylation-specific polymerase chain reaction (PCR) (MSP) is frequently used to study gene silencing by promoter hypermethylation. However, non-specific primer design can lead to false-positive detection of methylation. We present a novel, web-based algorithm for the design of primers for bisulfite-PCRs (MSP, sequencing, COBRA and multiplex-MSP), allowing the determination of a specificity score, which is based on the thermodynamic characteristics of the primer 3 0 -end. PCR amplification with primers not reaching a high specificity score can result in false-positive findings. We used MSPprimer to design MSP primers for analysis of the ATM promoter. In 37 non-small cell lung cancer (NSCLC) samples and 43 breast cancer samples no promoter methylation was detected. Conversely, published MSP primers not reaching the required specificity score led to non-specific amplification of DNA not converted by bisulfite. The result was a false-positive incidence of ATM promoter methylation of 24% in NSCLC and 48% in breast cancers, similar to published studies. This highlights the critical need for specific primer design for MSP. MSPprimer is a convenient tool to achieve this goal, which is available free of charge to the scientific community.
Introduction
The methylation of cytosine-guanine (CpG) dinucleotides in the promoter region of genes is an important mechanism of epigenetic gene regulation. It has been recognized that aberrant methylation of tumor suppressor genes plays an important role in carcinogenesis (Herman and Baylin, 2003) . The relative ease by which these methylation changes can be studied holds great promise for the development of diagnostic or prognostic biomarkers in oncology. Most assays for the study of methylation changes rely on the fact that treatment of genomic DNA with sodium bisulfite leads to deamination of unmethylated cytosines to uracils, with retention of the methylated cytosines (Clark et al., 1994) . This results in the generation of non-complementary singlestranded DNA, which can be used for polymerase chain reaction (PCR)-based analysis.
The most frequently used methods are bisulfite sequencing (Frommer et al., 1992) , COBRA assay (Xiong and Laird, 1997) , methylation-specific PCR (MSP) (Herman et al., 1996) and nested MSP, which allows the amplification of even heavily fragmented DNA from paraffin-embedded tissue (Brandes et al., 2005) . Optimal primer design is critical to achieve reliable results, and must take several factors into account that might jeopardize specific and robust amplification: (a) PCR primers must overlap non-CpG cytosines to amplify specifically only bisulfite converted sequences and not any non-converted DNA which is present after nearly every bisulfite reaction. (b) Primers must contain several CpGs to distinguish between methylated and unmethylated DNA. (c) Primers that lead to nonspecific products must be eliminated. This possibility is greater as following bisulfite conversion the complexity of the human genome is reduced to three rather than four bases. (d) Elimination of primers, which form secondary structures or primer-dimer pairs. The likelihood of these problems is increased, as the relative AT richness of bisulfite-specific primers results in a need for longer primers than typically used for the amplification of unmodified DNA.
PCR amplification with MSP primers that do not follow such rules could lead to false-positive results. This has been previously pointed out for the methylation analysis of the p53 promoter in myeloma cell lines (Brandes and Herman, 2006) . The possibility of falsepositive results owing to non-specific primer design is also suggested in the analysis of the ATM promoter in breast cancers, where results vary between 80% methylation and 0% methylation (Allinen et al., 2002) , as different primer sets were used.
To facilitate specific primer design for MSP, nested MSP, bisulfite sequencing and the COBRA assay, we developed a novel World Wide Web based computer algorithm, termed MSPprimer. The design of this program is outlined in Figure 1 . The specificity prediction is based on the thermodynamic characteristics of the 3 0 end of the proposed primer (Miura et al., 2005) and the number and position of CpG dinucleotides and non-CpG cytosines, respectively. Existing programs for bisulfite PCR primer design, 'Methprimer' (Li and Dahiya, 2002) and 'Bisearch' (Tusnady et al., 2005) fall short in this regard, as they are adaptations from general PCR primer design algorithms, which do not address the specificity concerns of methylation analysis and bisulfite conversion sufficiently.
We demonstrate that through the calculation of specificity scores for the distinction between bisulfite modified and unmodified DNA and methylated and unmethylated DNA, false-positive PCR results can be prevented. We validate the algorithm by comparison with published primer sequences and primers designed with alternative programs and address the controversy of ATM gene silencing through promoter hypermethylation through a thorough methylation analysis of the ATM promoter in non-small cell lung cancers (NSCLCs), breast cancers and the colon cancer cell line Hct-116, which has been previously reported to have a hypermethylated ATM promoter.
Results

DSDSS1
and DSDSS2 determine the specificity of a primer PCR primers were designed for three genes p16, MGMT and ATM with MSPprimer or the previously published web-based programs 'Methprimer' and 'Bisearch' or obtained from the literature. For each MSP primer, two scores were calculated using the MSPprimer algorithm, DSDSS1 for the distinction between bisulfite modified and unmodified DNA and DSDSS2 for the distinction between methylated and unmethylated DNA. The primer sequences and characteristics are provided in Table 1 . Results of these analyses are shown in Figure 2 .
A first potential problem in primer design occurs when designed primers fail to amplify from bisulfiteconverted DNA. No amplification was observed with three primer pairs: 'MP-BSP' and 'BS' for the amplification of the ATM promoter and 'MP-BSP2' for the amplification of the MGMT promoter. All three primer pairs have a significant discrepancy in melting temperature (T m ), which is the most likely explanation for the failure to amplify.
A second problem is observed when amplification occurs on non-bisulfite converted DNA. Primer pairs that did not sufficiently distinguish between bisulfite modified and non-modified DNA were 'BSP-2', 'Vo' and 'Ai' for ATM-specific PCRs. 'BSP-2' is a modification of 'BSP-1', replacing the only specificity determining base in the SDSS of these primers (displayed by lower case letters) with the ambiguous bases 'Y' or 'R', reducing the DSDSS1 from '3' to '0'. The DSDSS1 of both the 'Vo' and 'Ai' primer were '0' and '1' respectively. All primers with a DSDSS1 of '3' or greater produced specific results.
Finally, a third problem, unique to MSP, occurs when differences in DNA methylation cannot be accurately determined. Insufficient distinction between methylated and unmethylated DNA was observed for PCRs with the 'MP-1' primerpairs for the amplification of the ATM and MGMT promoters, designed with the default settings of 'Methprimer'. The DSDSS2 was '1' and '4' (ATM) and '1' and '5' (MGMT), respectively. All other primer pairs with a DSDSS2 of greater than '5' produced specific results. On the basis of these results, a cutoff value of greater than '2' for the DSDSS1 and greater than '5' for the DSDSS2 was incorporated into the MSPprimer algorithm. Primer sequences with lower scores will not be considered.
MSP for p16 and MGMT in NSCLC For further validation, we performed MSP using NSCLC primary tumor samples with previously published primers for p16 (JH-p16) and MGMT (JH -MGMT) and compared the results to those obtained with the 'MSP' primers for those genes. For both genes, there was a very high concordance of identical results (97% for MGMT and 93% for p16), indicating a high degree of reproducibility of results obtained with specific MSP primers even when the sequences and the primer locations are not absolutely identical. The three different methylation results (Figure 2d ) may reflect heterogeneity of methylation at individual sites in these tumors, but the overall methylation frequencies were nearly identical for both genes.
MSP for ATM in lung and breast cancer samples leads to different results based on the primer design The nonspecific amplification of unconverted DNA by the 'Ai' and the 'Vo' primersets raises the possibility that the methylation of the ATM promoter has been overestimated in NSCLC and breast cancer studies. We thus compared MSP performed with the 'Vo' primerset with MSP primers ('MSP2' and 'MSP3' for NSCLC samples and 'MSP2' for breast cancer samples) designed with the default settings of MSPprimer. The 'MSP3' primers are located in the vicinity of the 'Vo' primers, whereas the 'MSP2' primerset is further 5 0 to this region ( Figure 3a ). Apparent methylation is observed in the PCR with the 'Vo' primerset in 9/37 (24%) of NSCLC samples and 21/43 (48%) of breast cancer samples (Figure 3b and c).
No methylation is observed with the MSPprimer primersets. To determine whether the amplification of DNA in this setting was owing to true methylation of this region or a false-positive result produced by nonspecific amplification, direct sequencing of PCR products was performed. This demonstrates that the amplification with the 'Vo' primerset was of genomic, unconverted DNA (Figure 3d ), and not methylated bisulfite converted DNA. Owing to the conversion of CpG sites to UpG sites in unmethylated sequences, the 'Vo' primer for the amplification of the unmethylated sequence reach a higher specificity score and do not amplify unconverted DNA (Figure 3b ).
Bisulfite sequencing of Hct-116 cells
Differential methylation between primersets could possibly be observed if certain CpG dinucleotides were preferentially methylated. As the presence of stromal and inflammatory cells with unmethylated alleles in a tumor sample can alter the results of bisulfite sequencing analysis, this question is best addressed in a cell line system. The HCT-116 colon cancer cell line has been reported to contain ATM promoter hypermethylation, based upon differential digestion of a PCR product with the HpaII/MspI restriction enzymes (Kim et al., 2002) . Results of this study have been confirmed by MSP using the 'Vo' primerset . However, bisulfite sequencing of the ATM promoter in Hct-116 has not been published. We performed bisulfite sequencing of the ATM promoter over a range of 450 bases in the MSP analysed region. Only one methylated CpG dinucleotide was found in all the cloned sequences examined (Figure 4 ). This CpG was not assessed with either the 'Vo' or the 'MSP2' and 'MSP3' primersets, suggesting that the observed differences in methylation in lung and breast cancer in this study and published reports are not owing to methylation of individual CpG dinucleotides. (Esteller et al., 2000; Hegi et al., 2005) . A clinically applicable test requires a high degree in sensitivity and specificity. False-positive or false-negative results could lead to inaccurate treatment decisions. The efficiency of PCR depends on the priming efficacy of each primer pair, which in addition to the length of the PCR product, is determined by the characteristics of each primer pair, including secondary structure formation, primer-primer dimer formation and the risk for false-priming. Miura has shown in the budding yeast genome that an increasing incidence of false-priming in the 3 0 end of a primer, defined by the SDSS, rather than by the entire primer sequence, was a good predictor for decreased PCR efficiency (Miura et al., 2005) . This principle has been incorporated into MSPprimer. The likelihood for mismatches of the SDSS is reduced by favoring primers with longer SDSS and less frequent ambiguous bases.
The specificity of a MSP reaction is at least equally important and requires the correct distinction between methylated and unmethylated DNA and between bisulfite-modified DNA and unmethylated DNA. We have shown here that the specificity can be predicted based on the DSDSS1 and DSDSS2. We have also shown that primers that do not meet those minimal requirements will lead to false-positive methylation results. We identified a DSDSS1 of at least '3' as the cutoff value for specific amplification and a DSDSS2 of greater than '5'. All PCR with primers that were designed using this algorithm produced specific results. Primers that were designed with the default parameters of the 'Methprimer' program were not specific enough to distinguish between methylated and unmethylated DNA. However when the parameters were changed to include more CpGs, specificity was achieved. Primers designed with the 'Bisearch' program and two sequencing primer pairs designed with 'Methprimer' did not amplify a product, presumably owing to large discrepancies in the Tm of the primer pairs. We found that 'Methprimer' overestimated the Tm of very AT-rich primers. A possible explanation is that the underlying formula is not based on nearest-neighbor thermodynamic parameters but on length of the oligo and GC content.
The ATM protein is a critical mediator of DNA damage response following double-stranded breaks. Loss of ATM function renders cells highly susceptible to ionizing radiation. In lymphoid malignancies, inactivating mutations and genetic deletion of the ATM locus are associated with poor prognosis (Austen et al., 2005) . Silencing of ATM by promoter hypermethylation has been described in several studies (Ai et al., 2004; Vo et al., 2004; Bolt et al., 2005; Safar et al., 2005; Roy et al., 2006) . It has been linked to favorable prognosis in Figure 2 PCRs with the primer pairs detailed in Table 1 were analysed. Bisulfite (NaBi) treated and non-treated lymphocyte DNA (L) and in vitro-methylated DNA (M) were used as templates. An MSP of the ATM. DSDSS1 score of '3' was the minimal score that would predict specificity for the distinction between bisulfite modified DNA and non-modified DNA. The three primer pairs with a lower DSDSS1 were the 'BSP2', 'Vo' and 'Ai' primers. All primerpairs with a DSDSS2 score of '5' and greater allowed distinction between methylated and unmethylated DNA.
NSCLC (Safar et al., 2005) and to increased radiosensitivity in human glioma cell lines (Roy et al., 2006) . However, all studies reporting ATM methylation used MSP with either the 'Vo' Bolt et al., 2005) or 'Ai' (Ai et al., 2004; Safar et al., 2005; Roy et al., 2006) primers. Studies that analysed the ATM promoter either by bisulfite sequencing or by MSP using different primers failed to detect methylation in breast cancer (Allinen et al., 2002) , adult (Luo et al., 1998; Gronbaek et al., 2002) or pediatric lymphoid malignancies (Gumy-Pause et al., 2006) . DSDSS1 and DSDSS2 for the primers used in this MSP analysis were '10' and '0' for the sense primer and '18' and '12' for the antisense primer (Gronbaek et al., 2002) . As no methylation was observed, it appears that the high DSDSS2 score of the antisense primer was sufficient to compensate for the low score of the sense primer.
Our data suggest that ATM methylation in NSCLC and breast cancers has been overestimated. We found no evidence that ATM is hypermethylated in lung or breast cancer, or the colon cancer cell line HCT16. Findings using 'Vo' and 'Ai' primers are explained by insufficient distinction between bisulfite modified and unmodified DNA. The reason for the low specificity of those primers is an insufficient number or poor positioning of nonCpG cytosines. The former is particularly true for the 'Vo' sense primer, which does not have any non-CpG cytosinees and for the 'Ai' antisense primer where one non-CpG cytosinee is not enough to guarantee specificity, even when located in the most 3 0 position. The latter also applies to the 'Vo' antisense primer and the 'Ai' sense primer. Although these primers have two and three non-CpG cytosines respectively, their position is too far 5 0 to raise the DSDSS1 above '0' and '1' (Table 1) .
However, not all evidence for epigenetic regulation of ATM gene is based on MSP data. Increased ATM protein expression is observed after treatment with 6 mM azacytidine in U87 glioma cells (Roy et al., 2006) and 10 mM azacytidine in Hct-116 colon cancer cells ( Kim et al., 2002) . Before treatment with azacytidine, ATM expression is not completely silenced, as usually observed for hypermethylated genes. In fact, treatment of U87 cells at a dose of 3 mM azacytidine, a dose at which DNA methyltransferase inhibition occurs, fails to upregulate ATM expression, suggesting that an alternative mechanism might be responsible for increased ATM expression. Such a mechanism has been described for p53 in response to DNA damage (Karpf et al., 2001) .
Second, we could not confirm ATM promoter methylation in the Hct-116 cell line by bisulfite sequencing. One explanation for the discrepancy is the possibility that different culture conditions or different passage numbers had induced ATM methylation differences in the Hct-116 cell lines. This explanation would not address the fact that complete promoter demethylation after treatment with azacytidine as reported is usually not observed (Stresemann et al., 2006) . Even at high concentrations of azacytidine, the total methylCpG content is generally only reduced by about 40% and individual promoters retain a significant number of methylated CpGs (Stresemann et al., 2006) . Hence, one would have expected a partially methylated instead of a fully demethylated promoter.
Third, bisulfite sequencing data support the notion that at least some primary breast and head and neck tumors (Bolt et al., 2005) show methylation of the ATM promoter. However, these data are in direct contradiction with the extent of methylation demonstrated using MSP for these tumor samples . Although bisulfite sequencing of those samples shows complete methylation of nearly all CpGs in each clone sequenced, MSP with primers specific for the unmethylated product is more prominent than the methylated. It would be expected that sequencing would have found methylation in only a percentage of the cloned alleles, given the MSP results.
In summary, we developed a novel computer algorithm, which facilitates the design of specific primers based on the thermodynamics of the 3 0 end of the primer. Specificity scores and use of nearest-neighbor thermodynamics for T m prediction are potential advantages over existing algorithms. As shown for p16 and MGMT, use of specific primers guarantees reproducibility of results. The question whether the ATM gene is regulated through promoter hypermethylation remains controversial. We show here that the true incidence of ATM promoter methylation in NSCLC and breast cancer is likely overestimated in the literature owing to non-specific MSP primer design.
Materials and methods
Computer programming
Programming was carried out using the Perl programming language. The program is a combination of modules for the detection of CpG islands, the identification of candidate primer sequences, the calculation of their SDSS, DSDSS1 and DSDSS2, the determination of secondary structure and primer dimer formation. The program runs on a Linux-based web server and is accessible at www.mspprimer.org/cgi-mspprimer/ design.cgi. CpG island detection and primer design is based on sliding window algorithms as outlined in Figure 1 .
Calculation of T m s T m estimates are based on nearest neighbor thermodynamic parameters. The salt correction is based on a recently published formula (Owczarzy et al., 2004) and assumes a Na þ concentration of 50 mM and a primer concentration of 0.25 mM.
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-500 -450 -400 -350 -300 distance from TSS clone no. Figure 4 Bisulfite PCR was performed with two different ATM-specific primer sets in the Hct-116 cell line. Products were cloned and sequenced. No significant methylation of the ATM promoter was found.
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Calculation of specificity scores
The SDSS subsequence is calculated as described for each (Miura et al., 2005) . This calculation is largely dependent on the free energy DG (SantaLucia et al., 1996) and the annealing temperature. Single-base mismatches decrease DG and thus increase the SDSS. The thermodynamic parameters for singlebase mismatches SantaLucia, 1997, 1998a, b, c; Peyret et al., 1999) allow to the calculation of a score to determine the specificity of priming for bisulfite converted vs non-modified DNA (DSDSS1) and for methylated vs unmethylated DNA (DSDSS2).
Determination of secondary structure and primer-primer dimer formation A previously described algorithm is used to detect and eliminate primers that would form primer dimers or secondary structures (Vallone and Butler, 2004) .
Elimination of false-priming events possibly leading to competing products False-priming is assumed to be a possibility if one primer binds at least with its SDSS in a 300 base distance of the binding site of the other primer. These primer pairs will not be displayed. Two SDSS matches alone are not sufficient for effective amplification and are hence ignored. The chance for falsepriming is arithmetically kept at approximately 0.002% by the following assumptions, which all primers must fulfill: A primer length of at least 18 bases plus 1 base for any ambiguous base (thymidine or adenine) guarantees a high complexity of the primer (4 18 ). Given the size of the human genome of 3.2 Â 10 9 bases, chances that such a primer binds more than once in the human genome is about 0.5%. A length of the SDSS of at least 8 plus 1 base for every two ambiguous bases results in a complexity of 4 8 and a likelihood of 0.4% that there is a SDSS match in any 300 bp stretch of genomic sequence.
Sample selection
Breast cancer and NSCLC samples were obtained from the Department of Pathology at the Johns Hopkins Hospital according to institutional guidelines. All patients with breast tumors had axillary nodal involvement (N1-disease). Clinical stages for NSCLC were stage I and II. The distribution between adeno-and squamous cell carcinoma was even. DNA extraction was as described previously (Brandes et al., 2005) .
Cells lines used were HCT-116 as described previously (Herman et al., 1996) .
Bisulfite modification
Bisulfite modification was carried out using a commercially available kit (Zymo Research, Orange, CA, USA). About 1 mg of DNA was used for each reaction.
MSP
The genomic sequence for the p16, MGMT and ATM genes and 1000 bases upstream was obtained from the UCSC genome browser website. (http://genome.ucsc.edu). Primers were designed using the MSPprimer algorithm based on the length of the SDSS and increasing values of DSDSS1 and DSDSS2. Two primer pairs were designed using the Methprimer algorithm (http://www.urogene.org/methprimer/). MP1 was based on the default parameters, MP2 based on parameters that included more CpGs. One primerpair was designed with the Bisearch algorithm (http://bisearch.enzim.hu/) and four primer pairs were obtained from the literature (Herman et al., 1996; Ai et al., 2004; Vo et al., 2004; Brandes et al., 2005) . Primer sequences and characteristics are displayed in Table 1. DNA isolated from normal peripheral lymphocytes from healthy individuals served as a negative methylation control. Human placental DNA was treated in vitro with SssI methyltransferase (NEB, Beverly, MA, USA) to create a completely methylated DNA at all CpG-rich regions. In vitro methylated DNA served as the positive methylation control. PCR conditions were as described previously (Herman et al., 1996) . All PCR for newly designed primers were carried out over 35 cycles. PCR for the previously published primers were carried out as described. MSP products were analysed on 6% polyacrylamide gel electrophoresis.
PCR product purification and sequencing Automated sequencing (Johns Hopkins University School of Medicine Biosynthesis and Sequencing Facility, Department of Biological Chemistry, Baltimore, MD, USA) was either performed directly on PCR products after purified using a commercially available kit (Qiagen, Valencia, CA, USA) or after cloning into competent bacteria using the TOPO cloning kit (Invitrogen, Carlsbad, CA, USA) and subsequent plasmid mini preparation (Promega, Madison, WI, USA).
